THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Assessing the impact of in-utero exposures: potential effects of paracetamol on male reproductive development

Citation for published version:

Kilcoyne, K & Mitchell, R 2017, 'Assessing the impact of in-utero exposures: potential effects of paracetamol on male reproductive development', *Archives of Disease in Childhood*. <https://doi.org/10.1136/archdischild-2016-311374>

Digital Object Identifier (DOI):

<http://dx.doi.org/10.1136/archdischild-2016-311374>

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Archives of Disease in Childhood

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Archives of
Disease in Childhood**Assessing the impact of in-utero exposures: potential effects of paracetamol on male reproductive development**

Journal:	<i>Archives of Disease in Childhood</i>
Manuscript ID	archdischild-2016-311374.R1
Article Type:	Review
Edition:	not in use
Date Submitted by the Author:	n/a
Complete List of Authors:	Kilcoyne, Karen; University of Edinburgh, MRC Centre for Reproductive Health Mitchell, Rod; University of Edinburgh, MRC Centre for Reproductive Health; Royal Hospital for Sick Children, Department of Diabetes and Endocrinology
Keywords:	Testis, Fertility, Paracetamol, Fetal, Environmental exposure

SCHOLARONE™
Manuscripts

Assessing the impact of *in-utero* exposures: potential effects of paracetamol on male reproductive development

Karen R. Kilcoyne & Rod. T. Mitchell*

* Correspondence to:

Dr. Rod T. Mitchell, MRC Centre for Reproductive Health, University of Edinburgh, The Queen’s Medical Research Institute, Edinburgh, EH16 4TJ, UK. Email: Rod.mitchell@ed.ac.uk

ABSTRACT

Human male reproductive disorders (cryptorchidism, hypospadias, testicular cancer and low sperm counts) are common and some may be increasing in incidence worldwide. These associated disorders can arise from subnormal testosterone production during fetal life. This has resulted in a focus on *in-utero* environmental influences that may result in reproductive effects on the offspring in later life. Over recent years, there has been a dramatic increase in the scientific literature describing associations between *in-utero* environmental exposures (e.g. industrial chemicals and pharmaceuticals) and subsequent reproductive outcomes in male offspring. This includes studies investigating a potential role for *in-utero* analgesic exposure(s) on the fetal testis; however, providing definitive evidence of such effects presents numerous challenges. In this review, we describe an approach to assessing the potential clinical relevance of *in-utero* (and postnatal) environmental exposures on subsequent male reproductive function using exposure to the analgesic paracetamol as an example.

Male Reproductive Disorders and Testicular Dysgenesis Syndrome

From the mid 1900's to the present date, many studies have reported evidence for an increasing secular trend in the most common male reproductive abnormalities including hypospadias, cryptorchidism, low sperm counts¹⁻⁵ and testicular germ cell cancer (TGCC)⁶⁻¹⁰. Over the past 30 years, the incidence of TGCC has increased substantially¹⁰ and epidemiological studies predict that the incidence in Europe will increase by a further 24% by 2025^{9,11}.

The term 'testicular dysgenesis syndrome' (TDS) is often used to describe this group of individual disorders due to their frequent association and their relationship to impaired androgen production/action during fetal life. Genetic causes of impaired androgen action include androgen insensitivity syndrome (AIS), caused by a mutation in the androgen receptor in XY individuals, which results in under-masculinisation of the external genitalia, which can result in a typical female appearance in the complete (CAIS) form. AIS also includes features consistent with TDS (hypospadias, cryptorchidism, infertility and an increased risk of TGCC)^{12,13}. Although it is clear that many TDS disorders can arise as a result of genetic abnormalities, there is increasing evidence that *in-utero* environmental factors (including lifestyle and chemical exposures) may also play a role (Figure 1)^{3,14,15,16}.

Studies in rodents have demonstrated that perturbation of androgen production/action during fetal life results in the development of TDS disorders in male offspring¹⁷⁻²². These studies involve *in-utero* exposure to a plasticising agent (Di-n-butyl phthalate; DBP) which results in subsequent cryptorchidism, hypospadias, impaired spermatogenesis and primary hypogonadism. Crucially, there is a critical window of sensitivity in fetal life, termed the 'masculinisation programming window' (MPW), during which the subsequent development of these disorders may be programmed by lack of androgen production or action¹⁹. The MPW has been shown to occur between embryonic day (e)15.5 – e18.5 in rats and has been estimated to correspond to 8-14 weeks of gestation in humans^{19,22}.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

One of the challenges in understanding the development of these disorders in humans has been the assessment of fetal androgen exposure in male offspring. Measurement of anogenital distance (AGD), which is sexually dimorphic, can be used as a biomarker/read-out of fetal androgen exposure, and thus are a proxy for anti-androgenic effects of in-utero exposures²³⁻²⁵ that can be utilised throughout life^{25 26}. AGD is reduced in boys presenting during the neonatal period with cryptorchidism and/or hypospadias²⁷ and in adulthood, AGD has been shown to be positively associated with semen quality^{28 29} and serum testosterone²³. It should be emphasised that whilst measuring AGD can be used for carefully conducted population-based studies, technical difficulties, in terms of accuracy of measurement, reproducibility and time required to conduct this examination, limit its utility for clinical assessment of individuals.

The association between events that occur during fetal life and the development of male reproductive disorders, combined with the evidence to suggest a role for environmental influences has resulted in a large number of epidemiological and experimental studies investigating a range of chemical and pharmaceutical exposures. Recently a number of studies have described a potential role for analgesics in the development of these disorders³⁰⁻⁴⁰. In order to describe the potential effects of in-utero exposure to analgesics on male reproductive development we will first discuss in detail the development of the testis from fetal life focusing on cellular events that determine testosterone production and germ cell development. We will then briefly describe the approach to assessing in-utero environmental exposures before describing in detail the potential effects of paracetamol (the most commonly used analgesic worldwide) exposure during pregnancy, on male reproductive health in the offspring and subsequent generation(s).

Testicular Development and Function during Fetal and Early Postnatal Life

Formation of the testis

In order to understand the potential for *in-utero* exposures to affect the developing testis, it is important to understand testicular cellular development and function during fetal life and the early postnatal period (Figure 2). Primordial germ cells (PGCs) emerge at 4-5wks post conception in the human, and migrate from the yolk sac into the genital ridge where they become known as gonocytes⁴¹. Interaction between gonocytes and the stromal microenvironment, along with the presence of a single transcription factor coded by the Y chromosome, sex-determining region Y protein (SRY), determines gonadal sex. Following SRY expression, gonadal somatic cells, arising from the coelomic epithelium, begin to differentiate into Sertoli cells (SC)⁴². SC aggregate in a layer around gonocytes, thus forming the seminiferous cords at approximately 6-7 gestational weeks in the human (or e13 in the mouse)^{43 44}. The seminiferous cords separate the seminiferous epithelium, consisting solely of germ cells and SC, from the interstitial compartment, which includes the testosterone-secreting fetal Leydig cell population⁴⁵.

Sertoli cell (SC) development and function

SC play a vital role in supporting spermatogenesis in the adult testis. The total number of SC in adulthood determines final testis size, number of germ cells and maximum sperm output^{46 47 48}. However, SC also have important functions in fetal life including secretion of anti-Müllerian Hormone (AMH), necessary for regression of the Müllerian ducts, and factors (e.g. Desert Hedgehog) which induce fetal Leydig cell differentiation⁴⁹⁻⁵². SC proliferation in humans occurs during fetal and neonatal life followed by a quiescent period until the second proliferative wave around puberty⁴⁸. The switch from pre-puberty to puberty triggers the final maturation from proliferative immature SC to non-mitotic mature SC capable of supporting spermatogenesis (Figure 2). Rodent studies have indicated that prenatal exposures to plasticising chemicals known as phthalates can arrest SC development in their immature state, thus interfering with spermatogenesis^{18 21} and foci of immature SC are also a common feature in infertile men with azoospermia and other TDS disorders^{21 53}.

Germ cell development and fertility

During fetal and early postnatal life, the germ cells differentiate from gonocytes into spermatogonia during which they cease to express pluripotency markers (e.g. OCT4, Nanog)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

and begin to express germ cell-specific spermatogonial proteins (dDX4, MAGE-A4), a process that occurs asynchronously in humans from late second trimester to ~6 months postnatally⁵⁴. This period of germ cell development is important in establishing the spermatogonial stem cell pool, not only for future fertility but also because failure of gonocytes to differentiate into spermatogonia during fetal/early postnatal life is thought to result in germ cell neoplasia in-situ (GCNIS), which is the pre-malignant step towards TGCC in adulthood⁵⁵ (Figure 2). In addition to the increased risk of TGCC, individuals with TDS disorders may also exhibit dysgenetic areas in the testis in which germ cells are lost and seminiferous tubules become Sertoli cell-only (SCO). Therefore, environmental influences that impair germ cell development during fetal and early postnatal life may result in reduced fertility and/or the development of TGCC¹⁶.

Leydig cell development and function

Leydig cells (LC) are essential for endocrine function of the testis as they produce the steroid hormone testosterone. Testosterone is primarily required for fetal masculinisation (including testicular descent), pubertal development and spermatogenesis. LC development in the human is considered a 'triphasic event', as demonstrated by the peaks in plasma testosterone levels across the life course that coincide with the development of separate lineages of LC (Figure 2). A fetal LC population is present from 6 weeks gestation in humans (e12.5 in the mouse)⁵⁶⁻⁵⁹. By 2-3 months of postnatal life, a neonatal population is evident, responsible for the so-called 'mini-puberty'⁶⁰ and finally, an adult LC population arises at puberty and remains throughout adulthood⁶¹. Placental hCG initially stimulates testosterone production from the fetal LC and insufficiency in the former is associated with hypospadias and cryptorchidism⁶², whereas during the neonatal period, LH is responsible for stimulating the peak in plasma testosterone levels^{63 64}. In rodents, perturbations of fetal testosterone production (e.g. due to phthalate exposure) may result in some TDS disorders, including Leydig cell hyperplasia⁶² and has also been shown to be associated with primary hypogonadism/compensated LC failure in adulthood^{20 21}. Insulin-like factor 3 (Insl3) is another hormone produced by the Leydig cell which, like testosterone, plays a crucial role in testicular descent. Perturbations in Insl3 during the fetal period can also result in cryptorchidism in rodents^{65 66}.

Assessing the Impact of Environmental Exposures on Human Health

Studies aimed at investigating the impact of environmental exposures on human health largely consist of epidemiological studies in human populations and experimental animal studies. Whilst epidemiological evidence can demonstrate associations between exposures and occurrence of a condition, experimental studies can imply causation and demonstrate potential mechanisms. Critical assessment of the literature on effects of environmental exposures must take into account the strengths and limitations of these approaches (Table 1). We will describe the epidemiological and experimental evidence in relation to paracetamol exposure and the development of male reproductive disorders and in doing so we will illustrate some of the factors that need to be considered in order to critically assess such studies.

Effects of Exposure to Paracetamol on Male Reproductive Health

Maternal use of paracetamol during pregnancy

Avoidance of pain and pyrexia during pregnancy is important for fetal and maternal health and analgesics play an important role in the treatment of pain and pyrexia during pregnancy. In a large study of pregnant women from Europe, US and Australia (n=9,459), 81.2% reported taking over-the-counter (OTC) medicines⁶⁷. It is reported that >50% of pregnant women in the US take OTC analgesics, including paracetamol^{68 69}. Studies in the UK of self-reported medication use have shown that paracetamol is the most commonly used OTC medication during pregnancy, with 36% of pregnant women reporting paracetamol intake during the 1st trimester (n= 465/1305)⁷⁰ and 54% during the first 20 weeks of gestation⁷¹. In a similar Danish study, 47% of mothers reported taking paracetamol at some point during their pregnancy³⁰. Paracetamol readily crosses the placental barrier with a mean half-life of approximately 3 hours^{72 73} and its serum concentration is equivalent between mother and fetus following an oral therapeutic dose (1g)⁷⁴. The number of epidemiological and experimental studies into the potential relationship between analgesic exposure and male reproductive disorders have been increasing over recent years³¹.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Epidemiology of paracetamol exposure and male reproductive function

Epidemiological studies have reported associations between maternal use of analgesics and cryptorchidism in resulting male offspring^{30 32 33 75}; however, this is not consistent across all studies³⁴. Where associations exist, they appear to be restricted to exposure during the 2nd trimester or following prolonged exposure³⁵. The timing of exposure in relation to the critical period for programming male reproductive development is likely to be important. One study has reported an association between cryptorchidism and paracetamol exposure during the human MPW (estimated to be 8-14 gestational weeks¹⁹), however importantly, this was only statistically significant for prolonged exposure of >4 weeks³².

The reported association between exposure to paracetamol and cryptorchidism could be explained by a reduction in androgen (testosterone) production by the human fetal testis, and anogenital distance (AGD) has been shown to represent an ‘indirect’ postnatal readout of androgen exposure during fetal life²⁴. A recent prospective birth cohort study showed that 40% of women reported using paracetamol during the first 28 weeks of pregnancy³⁶. Exposure to a mixture of mild analgesics (including paracetamol and NSAIDs) was negatively associated with AGD in male infants (n=20; 3 months) which suggests reduced androgen signalling during fetal life. However, these results do not show a paracetamol-only induced effect and this may highlight the importance of exposure to ‘mixtures’ potentially resulting in additive effects which may be more representative of analgesic intake during pregnancy³⁶. A similar study (n=434 male infants) reported an association between paracetamol exposure and reduced AGD from birth to 2 years which was independent of body size³⁷ and interestingly, this association was limited to paracetamol exposure during the proposed human MPW (i.e. 1st trimester). Importantly, all of the above epidemiological studies are based on self-reporting of analgesic use, determined in most cases by the use of retrospective questionnaires. The possibility of inaccurate recall or recall bias and lack of direct measurements of analgesic exposure are important limitations of these studies.

Experimental approach to assessing the effect of paracetamol exposure during fetal life on male reproductive function

A variety of experimental approaches have been utilised to determine the effect of paracetamol exposure on the fetal testis, particularly in relation to testosterone production. This includes *in-vivo* approaches in pregnant rodents^{30 38 76 77} and *in-vitro* studies using fetal testis tissues from rodents^{30 78} and humans³⁹. Recently, a xenografting approach has been developed which can assess the effects of exposures on the human fetal testis in a more physiological manner than can be achieved *in vitro*³⁸.

To investigate potential paracetamol-induced effects during fetal life, pregnant rats were exposed to doses of 150, 250 or 350 mg/kg/day from e13-21. AGD was reduced in male offspring compared to untreated controls³⁰ with similar effects on AGD described in other studies^{38 77}. However, a recent study using the same regimen as described above (350 mg/kg/day from e13-21) did not demonstrate a significant effect on AGD⁷⁶. The timing of exposure in these studies coincides with the MPW; however, the doses (150-350mg/kg/d) used are higher than therapeutic doses (~60mg/kg/d) to which humans are usually exposed³⁸. There are also likely to be large differences in the pharmacokinetics and metabolism of these agents in rodents compared to humans, making direct correlations from dose effects between species challenging.

In-vitro paracetamol exposure studies have also been described using fetal rat testis explants (e14.5) cultured for 3 days in media containing paracetamol (1 μ M)^{30 78}. This resulted in a significant reduction in testosterone production, even at a concentration of 1 μ M, which is well below the therapeutic concentration described in human plasma (65-130 μ M) following paracetamol ingestion³⁰. This could suggest that *in-vitro* effects may under-estimate the effects that occur in humans, however it should be emphasised that circulating paracetamol levels may not be a direct indicator of intra-testicular levels. In addition, the *in-vitro* models cannot mimic the pharmacokinetics, including peak and trough concentrations that occur *in-vivo*.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The majority of experimental studies in rodents suggest a negative association between paracetamol exposure and fetal androgen production. This has prompted subsequent *in-vitro* studies using human fetal testis tissue. Exposure of first trimester testis (8-12 weeks gestation) to paracetamol (10 μ M) for 1 to 3 days did not alter testosterone production compared to vehicle-exposed controls³⁹. The differences between the results of the rodent and human *in-vitro* studies may relate to differences in the suitability of the *in-vitro* system or the timing of exposure in relation to the stage of development (including the timing of the MPW) between these two species³⁹. *In-vitro* culture conditions cannot replicate normal human testosterone production or the *in-vivo* environment. To circumvent some of these limitations, an *ex-vivo* xenograft approach can be undertaken to investigate potential paracetamol-induced effects on the human fetal testis^{79 80}. In this system, human fetal testis tissue pieces (n=5; 14-20weeks gestation) are grafted subcutaneously under the dorsal skin of castrate host nude mice. Paracetamol was then administered orally to the host animal according to a therapeutic regimen (20mg/kg; 3 times daily), resulting in a significant reduction (45%) in host serum testosterone after 7 days' paracetamol exposure, whilst a single day's exposure did not affect testosterone production³⁸. Interestingly, plasma paracetamol concentrations, measured 1 hour after the final dose³⁸ were significantly lower compared to post-therapeutic levels reported in pregnant women⁷² suggesting that the effects on testosterone can occur at clinically relevant paracetamol doses/exposures. The effect of prolonged paracetamol exposure of xenografts³⁸ is in contrast to the results obtained from *in-vitro* culture of human fetal testis tissue³⁹. This could be due to the method of delivery (media versus oral administration), timing of exposure *in-vitro* (8-12 weeks gestation) compared to xenografts (14-20 weeks gestation), the relative dosage, length of exposure or difference in metabolism between *in-vivo* and *in-vitro* studies. Further limitations of both the *in-vitro* and xenograft systems include the lack of a feto-placental unit, although it has been demonstrated that paracetamol is able to cross the placenta and enter the fetal circulation in similar concentrations to maternal plasma^{72 73}.

Overall, the results of the experimental studies suggest that exposure to paracetamol during fetal life may lead to a reduction in testosterone production in humans, although direct correlation between the degree and duration of reduced testosterone and the potential to develop male reproductive disorders cannot be made from these studies. Whilst the majority of circulating paracetamol in humans comes from ingestion of paracetamol

274 containing medications, an alternative source of paracetamol has also recently been
275 described. The industrial chemical aniline, which is found in a wide variety of manufactured
276 products e.g. pharmaceuticals, cosmetics, cigarette smoke, has been shown to be rapidly
277 metabolised to paracetamol inside the body^{81 82}. *In-vivo* studies involving *in-utero* exposure
278 of male mice to aniline have shown similar fetal anti-androgenic effects to those described
279 for exposure to paracetamol⁷⁷.

280
281 It is known that analgesics, including paracetamol, can inhibit prostaglandin synthesis⁸³.
282 During fetal life, germ cells have been shown to be prostaglandin targets^{84 85} indicating that
283 germ cells may also be susceptible to analgesic-induced changes, which in turn may alter GC
284 development and fertility in the offspring. To investigate this, *in-vivo* studies of *in-utero*
285 paracetamol exposure have been conducted in rodents^{85 86}. In one study, pregnant rats
286 were exposed to paracetamol (350mg/kg/d) from e15.5-18.5, which resulted in altered
287 germ cell development in both sexes of offspring⁸⁵. In males there was an accelerated loss
288 of expression of a pluripotency marker (OCT4), suggesting germ cell differentiation from
289 gonocyte to spermatogonia had occurred prematurely. It is interesting to note that the
290 effects on germ cell differentiation in F1 males occur during the MPW, a critical period for
291 male reproductive development^{21 85}. In F1 females there was a delay in meiotic entry in
292 oogonia. After *in-utero* paracetamol exposure, female offspring had reduced ovary size and
293 exhibited reduced litter size in adulthood, whilst no reproductive effects were seen in
294 males, suggesting a potential compensatory mechanism between fetal life and adulthood⁸⁵.
295 In another study, exposure of pregnant rats to a much lower dose of paracetamol
296 (50mg/kg/d) from 7 days post-conception to birth resulted in a reduction in follicle number
297 at 2 months postnatally and also a reduction in pups per litter at 6 months of age⁸⁶.

298
299 During fetal life, germ cells undergo epigenetic reprogramming⁸⁷ which suggests that any
300 perturbations to germ cells during this period could have inter-generational effects. The
301 potential for such effects occurring following *in-utero* paracetamol exposure was
302 investigated in a recent study in which paracetamol-exposed (male and female) mice were
303 mated with a non-exposed partner. The subsequent F2 females had reduced ovary weight

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(as previously described) and reduced number of primordial follicles, whilst F2 males did not appear to have any demonstrable germ cell effects⁸⁵.

Postnatal effects of paracetamol exposure on male reproductive function

Whilst the majority of studies have investigated the effect of analgesic exposure on the fetal testis, one study has demonstrated that the adult testis may be susceptible to endocrine perturbations following paracetamol exposure. Explants from human adult testis (average age: 79.8 ± 5.6 years) were cultured *in vitro* with therapeutically relevant doses of paracetamol for 24 hours, resulting in a significant reduction in testosterone production in the presence of 10⁻⁴ or 10⁻⁵M paracetamol (30% and 18% reduction respectively)⁸⁸. To date no studies have been conducted to assess the effect of analgesic use in adult men in terms of testosterone production or testicular function.

Analgesics are also commonly used in paediatrics; however, to our knowledge, there have been no studies investigating the effect of analgesic exposure during the neonatal, infancy or childhood period in terms of later male reproductive function. In addition, the testicular effects of exposures on babies born pre-term has not been investigated. Pharmacokinetic studies have shown that based on body weight, neonates have approximately 30% paracetamol clearance capacity compared to adults⁸⁹⁻⁹¹. Exposure during the neonatal period may be of particular importance given the programmed rise in testosterone during mini-puberty⁶⁴. Whether paracetamol exposure during this period can suppress testosterone and what the implications might be for subsequent reproductive health is unknown, although it is worth pointing out that in individuals with conditions such as hypogonadotrophic hypogonadism (in whom there is no rise in testosterone during mini puberty or at expected time of puberty), testicular function and fertility can be restored with exogenous gonadotrophins⁹². Given the relative quiescence of the HPG axis during the childhood period, it would be anticipated that the potential for anti-androgenic effects of analgesics would not be as important during this period compared to other stages throughout life; however, it is unknown whether exposures can affect Leydig, Sertoli or germ cell development during this period. Further studies are warranted to investigate the effects of exposure to analgesics during postnatal life.

Conclusion

Male reproductive disorders are common and some are increasing in incidence. These disorders can be associated and linked to a reduction in testosterone during fetal life. *In-utero* exposure to environmental agents are likely to play a role in the development of these disorders. In order to assess the potential impact of environmental agents on male reproductive function in humans, careful consideration of study methodology is required, particularly in relation to the model system and species, in addition to dose, route and duration of exposure. Effects of exposures, e.g. reduction in testosterone, must be considered in the context of the potential to result in a subsequent disorder such as cryptorchidism or reduced sperm production/counts. For *in-utero* paracetamol exposure, epidemiological studies demonstrate associations with cryptorchidism in the offspring, primarily in relation to exposures during the second trimester and prolonged duration of exposure, whilst experimental studies suggest that paracetamol can reduce testosterone production by the human fetal testis. Based on the current evidence discussed, it cannot be concluded that exposure to paracetamol is a direct cause of male reproductive disorders nor that analgesics should simply be avoided during pregnancy. The importance of managing pain and pyrexia during pregnancy should also be considered for the health of the mother and fetus. As a result, a pragmatic approach is to ensure that where analgesics are deemed to be necessary, that they are used at the minimum therapeutic dose for the shortest possible duration. Future studies should aim to determine the clinical relevance of the findings related to *in-utero* exposures, in addition to investigating the effects of exposures during postnatal life.

Acknowledgements

We thank Ronnie Grant for his assistance with the illustrations.

Financial support

RTM is supported by a Wellcome Trust Intermediate Clinical Fellowship (Grant No: 098522).

Conflicts of interest

None

References

1. Giwercman A. Declining semen quality and increasing incidence of abnormalities in male reproductive organs--fact or fiction? *Hum Reprod* 1995;**10 Suppl 1**:158-64.

2. Paulozzi LJ. International trends in rates of hypospadias and cryptorchidism. *Environ Health Perspect* 1999;**107**(4):297-302.

3. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. *Hum Reprod* 2001;**16**(5):972-8.

4. Acerini CL, Miles HL, Dunger DB, et al. The descriptive epidemiology of congenital and acquired cryptorchidism in a UK infant cohort. *Arch Dis Child* 2009;**94**(11):868-72.

5. Toppari J, Virtanen HE, Main KM, et al. Cryptorchidism and hypospadias as a sign of testicular dysgenesis syndrome (TDS): environmental connection. *Birth Defects Res A Clin Mol Teratol* 2010;**88**(10):910-9.

6. Richiardi L, Bellocchio R, Adami HO, et al. Testicular cancer incidence in eight northern European countries: secular and recent trends. *Cancer Epidemiol Biomarkers Prev* 2004;**13**(12):2157-66.

7. Bray F, Richiardi L, Ekbom A, et al. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. *Int J Cancer* 2006;**118**(12):3099-111.

8. Shah MN, Devesa SS, Zhu K, et al. Trends in testicular germ cell tumours by ethnic group in the United States. *Int J Androl* 2007;**30**(4):206-13; discussion 13-4.

9. Le Cornet C, Lortet-Tieulent J, Forman D, et al. Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data. *Eur J Cancer* 2014;**50**(4):831-9.

10. Znaor A, Lortet-Tieulent J, Jemal A, et al. International variations and trends in testicular cancer incidence and mortality. *Eur Urol* 2014;**65**(6):1095-106.

11. Chia NY, Chan YS, Feng B, et al. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. *Nature* 2010;**468**(7321):316-20.

12. Hughes IA, Davies JD, Bunch TJ, et al. Androgen insensitivity syndrome. *Lancet* 2012;**380**(9851):1419-28.

13. Mongan NP, Tadokoro-Cuccaro R, Bunch T, et al. Androgen insensitivity syndrome. *Best Pract Res Clin Endocrinol Metab* 2015;**29**(4):569-80.

14. Sharpe RM, Skakkebaek NE. Testicular dysgenesis syndrome: mechanistic insights and potential new downstream effects. *Fertil Steril* 2008;**89**(2 Suppl):e33-8.

15. Skakkebaek NE. A Brief Review of the Link between Environment and Male Reproductive Health: Lessons from Studies of Testicular Germ Cell Cancer. *Horm Res Paediatr* 2016;**86**(4):240-46.

16. Skakkebaek NE, Rajpert-De Meyts E, Buck Louis GM, et al. Male Reproductive Disorders and Fertility Trends: Influences of Environment and Genetic Susceptibility. *Physiol Rev* 2016;**96**(1):55-97.

17. Mylchreest E, Foster PM. DBP exerts its antiandrogenic activity by indirectly interfering with androgen signaling pathways. *Toxicol Appl Pharmacol* 2000;**168**(2):174-5.

18. Fisher JS, Macpherson S, Marchetti N, et al. Human 'testicular dysgenesis syndrome': a possible model using in-utero exposure of the rat to dibutyl phthalate. *Hum Reprod* 2003;**18**(7):1383-94.

19. Welsh M, Saunders PT, Fisker M, et al. Identification in rats of a programming window for reproductive tract masculinization, disruption of which leads to hypospadias and cryptorchidism. *J Clin Invest* 2008;**118**(4):1479-90.

20. Kilcoyne KR, Smith LB, Atanassova N, et al. Fetal programming of adult Leydig cell function by androgenic effects on stem/progenitor cells. *Proc Natl Acad Sci U S A* 2014;**111**(18):E1924-32.

21. van den Driesche S, Kilcoyne KR, Wagner I, et al. Experimentally induced testicular dysgenesis syndrome originates in the masculinization programming window. *JCI Insight* 2017;**2**(6):e91204.
22. Fowler PA, Bhattacharya S, Flannigan S, et al. Maternal cigarette smoking and effects on androgen action in male offspring: unexpected effects on second-trimester anogenital distance. *J Clin Endocrinol Metab* 2011;**96**(9):E1502-6.
23. Eisenberg ML, Shy M, Walters RC, et al. The relationship between anogenital distance and azoospermia in adult men. *Int J Androl* 2012;**35**(5):726-30.
24. Dean A, Sharpe RM. Clinical review: Anogenital distance or digit length ratio as measures of fetal androgen exposure: relationship to male reproductive development and its disorders. *J Clin Endocrinol Metab* 2013;**98**(6):2230-8.
25. Mendiola J, Onate-Celdran J, Samper-Mateo P, et al. Comparability and reproducibility of adult male anogenital distance measurements for two different methods. *Andrology* 2016;**4**(4):626-31.
26. Thankamony A, Pasterski V, Ong KK, et al. Anogenital distance as a marker of androgen exposure in humans. *Andrology* 2016;**4**(4):616-25.
27. Thankamony A, Lek N, Carroll D, et al. Anogenital distance and penile length in infants with hypospadias or cryptorchidism: comparison with normative data. *Environ Health Perspect* 2014;**122**(2):207-11.
28. Mendiola J, Stahlhut RW, Jorgensen N, et al. Shorter anogenital distance predicts poorer semen quality in young men in Rochester, New York. *Environ Health Perspect* 2011;**119**(7):958-63.
29. Eisenberg ML, Hsieh MH, Walters RC, et al. The relationship between anogenital distance, fatherhood, and fertility in adult men. *PLoS One* 2011;**6**(5):e18973.
30. Kristensen DM, Hass U, Lesne L, et al. Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat. *Hum Reprod* 2011;**26**(1):235-44.
31. Kristensen DM, Mazaud-Guittot S, Gaudriault P, et al. Analgesic use - prevalence, biomonitoring and endocrine and reproductive effects. *Nat Rev Endocrinol* 2016;**12**(7):381-93.
32. Jensen MS, Rebordosa C, Thulstrup AM, et al. Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. *Epidemiology* 2010;**21**(6):779-85.
33. Snijder CA, Kortenkamp A, Steegers EA, et al. Intrauterine exposure to mild analgesics during pregnancy and the occurrence of cryptorchidism and hypospadias in the offspring: the Generation R Study. *Hum Reprod* 2012;**27**(4):1191-201.
34. Philippat C, Giorgis-Allemand L, Chevrier C, et al. Analgesics during pregnancy and undescended testis. *Epidemiology* 2011;**22**(5):747-9.
35. Hurtado-Gonzalez P. In Press. 2017.
36. Lind DV, Main KM, Kyhl HB, et al. Maternal use of mild analgesics during pregnancy associated with reduced anogenital distance in sons: a cohort study of 1027 mother-child pairs. *Hum Reprod* 2017;**32**(1):223-31.
37. Fisher BG, Thankamony A, Hughes IA, et al. Prenatal paracetamol exposure is associated with shorter anogenital distance in male infants. *Hum Reprod* 2016;**31**(11):2642-50.
38. van den Driesche S, Macdonald J, Anderson RA, et al. Prolonged exposure to acetaminophen reduces testosterone production by the human fetal testis in a xenograft model. *Sci Transl Med* 2015;**7**(288):288ra80.
39. Mazaud-Guittot S, Nicolas Nicolaz C, Desdoits-Lethimonier C, et al. Paracetamol, aspirin, and indomethacin induce endocrine disturbances in the human fetal testis capable of interfering with testicular descent. *J Clin Endocrinol Metab* 2013;**98**(11):E1757-67.
40. Hurtado-Gonzalez P, Mitchell RT. Analgesic use in pregnancy and male reproductive development. *Curr Opin Endocrinol Diabetes Obes* 2017.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

41. Mamsen LS, Brochner CB, Byskov AG, et al. The migration and loss of human primordial germ stem cells from the hind gut epithelium towards the gonadal ridge. *Int J Dev Biol* 2012;**56**(10-12):771-8.

42. Cool J, Carmona FD, Szucsik JC, et al. Peritubular myoid cells are not the migrating population required for testis cord formation in the XY gonad. *Sex Dev* 2008;**2**(3):128-33.

43. O'Shaughnessy PJ, Fowler PA. Endocrinology of the mammalian fetal testis. *Reproduction* 2011;**141**(1):37-46.

44. Heeren AM, van Iperen L, Klootwijk DB, et al. Development of the follicular basement membrane during human gametogenesis and early folliculogenesis. *BMC Dev Biol* 2015;**15**:4.

45. Nel-Themaat L, Jang CW, Stewart MD, et al. Sertoli cell behaviors in developing testis cords and postnatal seminiferous tubules of the mouse. *Biol Reprod* 2011;**84**(2):342-50.

46. Johnson L, Zane RS, Petty CS, et al. Quantification of the human Sertoli cell population: its distribution, relation to germ cell numbers, and age-related decline. *Biol Reprod* 1984;**31**(4):785-95.

47. Orth JM, Gunsalus GL, Lamperti AA. Evidence from Sertoli cell-depleted rats indicates that spermatid number in adults depends on numbers of Sertoli cells produced during perinatal development. *Endocrinology* 1988;**122**(3):787-94.

48. Sharpe RM, McKinnell C, Kivlin C, et al. Proliferation and functional maturation of Sertoli cells, and their relevance to disorders of testis function in adulthood. *Reproduction* 2003;**125**(6):769-84.

49. Bitgood MJ, Shen L, McMahon AP. Sertoli cell signaling by Desert hedgehog regulates the male germline. *Curr Biol* 1996;**6**(3):298-304.

50. Pierucci-Alves F, Clark AM, Russell LD. A developmental study of the Desert hedgehog-null mouse testis. *Biol Reprod* 2001;**65**(5):1392-402.

51. Yao HH, Whoriskey W, Capel B. Desert Hedgehog/Patched 1 signaling specifies fetal Leydig cell fate in testis organogenesis. *Genes Dev* 2002;**16**(11):1433-40.

52. Griswold SL, Behringer RR. Fetal Leydig cell origin and development. *Sex Dev* 2009;**3**(1):1-15.

53. Rajpert-De Meyts E. Testicular Dysgenesis Syndrome and Carcinoma In Situ Testis. In: Jezek D, ed. *Atlas on the Human Testis*: Springer-Verlag London, 2013:159-78.

54. Mitchell RT, Cowan G, Morris KD, et al. Germ cell differentiation in the marmoset (*Callithrix jacchus*) during fetal and neonatal life closely parallels that in the human. *Hum Reprod* 2008;**23**(12):2755-65.

55. Rajpert-De Meyts E, McGlynn KA, Okamoto K, et al. Testicular germ cell tumours. *Lancet* 2016;**387**(10029):1762-74.

56. Reyes FI, Boroditsky RS, Winter JS, et al. Studies on human sexual development. II. Fetal and maternal serum gonadotropin and sex steroid concentrations. *J Clin Endocrinol Metab* 1974;**38**(4):612-7.

57. Tapanainen J, Kellokumpu-Lehtinen P, Pelliniemi L, et al. Age-related changes in endogenous steroids of human fetal testis during early and midpregnancy. *J Clin Endocrinol Metab* 1981;**52**(1):98-102.

58. Ostrer H, Huang HY, Masch RJ, et al. A cellular study of human testis development. *Sex Dev* 2007;**1**(5):286-92.

59. Baker PJ, Sha JA, McBride MW, et al. Expression of 3beta-hydroxysteroid dehydrogenase type I and type VI isoforms in the mouse testis during development. *Eur J Biochem* 1999;**260**(3):911-7.

60. Codesal J, Regadera J, Nistal M, et al. Involution of human fetal Leydig cells. An immunohistochemical, ultrastructural and quantitative study. *J Anat* 1990;**172**:103-14.

61. Prince FP. The triphasic nature of Leydig cell development in humans, and comments on nomenclature. *J Endocrinol* 2001;**168**(2):213-6.

62. Scott HM, Mason JJ, Sharpe RM. Steroidogenesis in the fetal testis and its susceptibility to disruption by exogenous compounds. *Endocr Rev* 2009;**30**(7):883-925.

63. Huhtaniemi I. Endocrine function and regulation of the fetal and neonatal testis. *Int J Dev Biol* 1989;**33**(1):117-23.
64. Mann DR, Fraser HM. The neonatal period: a critical interval in male primate development. *J Endocrinol* 1996;**149**(2):191-7.
65. Hughes IA, Acerini CL. Factors controlling testis descent. *Eur J Endocrinol* 2008;**159** Suppl 1:S75-82.
66. Ivell R, Anand-Ivell R. Biology of insulin-like factor 3 in human reproduction. *Hum Reprod Update* 2009;**15**(4):463-76.
67. Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. *BMJ Open* 2014;**4**(2):e004365.
68. Werler MM, Mitchell AA, Hernandez-Diaz S, et al. Use of over-the-counter medications during pregnancy. *Am J Obstet Gynecol* 2005;**193**(3 Pt 1):771-7.
69. McKenna L, McIntyre M. What over-the-counter preparations are pregnant women taking? A literature review. *J Adv Nurs* 2006;**56**(6):636-45.
70. Thorpe PG, Gilboa SM, Hernandez-Diaz S, et al. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. *Pharmacoepidemiol Drug Saf* 2013;**22**(9):1013-8.
71. Shaheen SO, Newson RB, Sherriff A, et al. Paracetamol use in pregnancy and wheezing in early childhood. *Thorax* 2002;**57**(11):958-63.
72. Rayburn W, Shukla U, Stetson P, et al. Acetaminophen pharmacokinetics: comparison between pregnant and nonpregnant women. *Am J Obstet Gynecol* 1986;**155**(6):1353-6.
73. Nitsche JF, Patil AS, Langman LJ, et al. Transplacental Passage of Acetaminophen in Term Pregnancy. *Am J Perinatol* 2016.
74. Naga Rani MA, Joseph T, Narayanan R. Placental transfer of paracetamol. *J Indian Med Assoc* 1989;**87**(8):182-3.
75. Berkowitz GS, Lapinski RH. Risk factors for cryptorchidism: a nested case-control study. *Paediatr Perinat Epidemiol* 1996;**10**(1):39-51.
76. Axelstad M, Christiansen S, Boberg J, et al. Mixtures of endocrine-disrupting contaminants induce adverse developmental effects in preweaning rats. *Reproduction* 2014;**147**(4):489-501.
77. Holm JB, Chalmey C, Modick H, et al. Aniline Is Rapidly Converted Into Paracetamol Impairing Male Reproductive Development. *Toxicol Sci* 2015;**148**(1):288-98.
78. Kristensen DM, Lesne L, Le Fol V, et al. Paracetamol (acetaminophen), aspirin (acetylsalicylic acid) and indomethacin are anti-androgenic in the rat foetal testis. *Int J Androl* 2012;**35**(3):377-84.
79. Mitchell RT, Childs AJ, Anderson RA, et al. Do phthalates affect steroidogenesis by the human fetal testis? Exposure of human fetal testis xenografts to di-n-butyl phthalate. *J Clin Endocrinol Metab* 2012;**97**(3):E341-8.
80. Mitchell RT, Saunders PT, Childs AJ, et al. Xenografting of human fetal testis tissue: a new approach to study fetal testis development and germ cell differentiation. *Hum Reprod* 2010;**25**(10):2405-14.
81. Modick H, Weiss T, Dierkes G, et al. Ubiquitous presence of paracetamol in human urine: sources and implications. *Reproduction* 2014;**147**(4):R105-17.
82. Modick H, Weiss T, Dierkes G, et al. Human metabolism and excretion kinetics of aniline after a single oral dose. *Arch Toxicol* 2016;**90**(6):1325-33.
83. Graham GG, Davies MJ, Day RO, et al. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. *Inflammopharmacology* 2013;**21**(3):201-32.
84. Bayne RA, Eddie SL, Collins CS, et al. Prostaglandin E2 as a regulator of germ cells during ovarian development. *J Clin Endocrinol Metab* 2009;**94**(10):4053-60.
85. Dean A, van den Driesche S, Wang Y, et al. Analgesic exposure in pregnant rats affects fetal germ cell development with inter-generational reproductive consequences. *Sci Rep* 2016;**6**:19789.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

86. Holm JB, Mazaud-Guittot S, Danneskiold-Samsoe NB, et al. Intrauterine Exposure to Paracetamol and Aniline Impairs Female Reproductive Development by Reducing Follicle Reserves and Fertility. *Toxicol Sci* 2016;**150**(1):178-89.

87. von Meyenn F, Berrens RV, Andrews S, et al. Comparative Principles of DNA Methylation Reprogramming during Human and Mouse In Vitro Primordial Germ Cell Specification. *Dev Cell* 2016;**39**(1):104-15.

88. Albert O, Desdoits-Lethimonier C, Lesne L, et al. Paracetamol, aspirin and indomethacin display endocrine disrupting properties in the adult human testis in vitro. *Hum Reprod* 2013;**28**(7):1890-8.

89. Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. *Arch Dis Child* 2011;**96**(6):575-80.

90. Allegaert K, Olkkola KT, Owens KH, et al. Covariates of intravenous paracetamol pharmacokinetics in adults. *BMC Anesthesiol* 2014;**14**:77.

91. Cook SF, Roberts JK, Samiee-Zafarghandy S, et al. Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation. *Clin Pharmacokinet* 2016;**55**(1):107-19.

92. Boehm U, Bouloux PM, Dattani MT, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment. *Nat Rev Endocrinol* 2015;**11**(9):547-64.

Figure Legends

Figure 1 – In-utero factors proposed to predispose to Testicular Dysgenesis Syndrome (TDS) disorders. Many lifestyle, genetic and environmental factors during fetal life have been postulated to lead to the development of TDS disorders in male offspring, albeit with variable (and in some cases limited) sources of evidence¹⁶.

Figure 2 – Testicular development in health and disease. Development of germ (green panel), Leydig (yellow panel) and Sertoli (purple panel) cells during different stages of testicular development. Differentiation of germ and Sertoli cells (dotted line) and the individual Leydig cell populations are shown. Note that for germ cells, failure of differentiation from gonocyte to spermatogonia leads to the development of pre-malignant Germ Cell Neoplasia In-Situ (GCNIS) cells which results in testicular germ cell cancer in young adulthood. The Masculinisation Programming Window (MPW; shaded box) is shown during fetal life in which reduced testosterone may result in the development of Testicular Dysgenesis Syndrome (TDS) disorders. Relative testosterone production during developmental periods is also indicated (black line).

Tables

<i>Epidemiological</i>
Study Design - descriptive, case-control or experimental, relevant population
Exposure - measured directly (agent) or indirectly (questionnaire, proxy exposure)
Effect - direct effect (e.g. cryptorchidism) or indirect (AGD)
Other - mechanistic plausibility for effects

<i>Experimental</i>
Model - species, experimental system (e.g. <i>in-vivo</i> , <i>in-vitro</i> , <i>ex-vivo</i>)
Agent - same agent or similar class/compound, metabolism of agent
Dosing - dose equivalent (e.g. serum/ <i>in-vitro</i> concentrations), timing, duration
Effect - direct effect (e.g. cryptorchidism) or proxy for clinical condition (AGD)
Mechanism - e.g. effect on signalling pathways (including rescue)

Table 1 – Key points to consider when assessing epidemiological and experimental studies relating to the effects of environmental exposures on male reproductive development.

Response to Reviewers

Reviewer(s)' Comments to Author:

Reviewer: 1

Comments to the Author

The paper is written by a research group which has been very active in research on impact of paracetamol on male development. It is often useful when researchers reflect on their recent results in an analysis of available data and put them into perspective. While I like the discussions on paracetamol I feel that the general aspects of the topic, as the title seems to suggest, are somewhat superficially analysed. I suggest that the title 'Assessing the impact of in-utero environmental exposures on male reproductive function and fertility' is changed to reflect this limitation of the paper and focus more on paracetamol.

We thank the reviewer for their helpful comments and we have taken these on board in the revised manuscript. It is important to bear in mind that this review was written with the ADC readership in mind and therefore is aimed at a general paediatric audience with the intention of introducing the concepts of assessing endocrine disruption using exposure to analgesics and impacts on male reproductive function to illustrate these points. We have however altered the text to make it clear in the introduction that the focus is on paracetamol (P1, Line 24; P3, Line 79-82). We have also altered the title to reflect this.

Specific points:

- 1) As the authors relate their findings to human TDS, the description of TDS seems to lack some important reported findings in these men, including the persistent dysgenetic, histological changes in the Sertolic and Leydig cells, which can be seen in adult men with the disorder (as described by Rajpert-De Meyts E. Hum Reprod Update. 2006).

This is an important point and we have included this in these points in the manuscript (P 5, Line 126-128).

- 2) The reader may get a wrong impresion of the doses of paracetamol generally used. On page 7, line 55 they write: ' ..... however, the doses (150-350mg/kg/d) used are higher than human therapeutic doses (~60mg/kg/d) to which humans are usually exposed.' This stqatement is not correct. 60mg/kg/d is a maximal 24 h dose, only used in severe pain. Unfortunately, previous papers have also exaggerated the doses of paracetamol most often used.

We respectfully disagree with this point. Paracetamol doses in children in the UK are prescribed according the British National Formulary. The therapeutic dose for pain/pyrexia is an initial loading dose of 20mg/kg and 10-15mg/kg 4-6hrly (maximum 4 doses/24 hrs). This equates to 60mg/kg/d and does not specifically apply to 'severe' pain. There may be variations in paracetamol dosing in different countries to which the reviewer is referring but it is reasonable to describe the stated doses as 'therapeutic dosing'. In addition, in xenograft studies paracetamol levels have been directly measured in the serum of the host mouse and have been shown to be below those measured in the serum of humans following a therapeutic dose.

- 3) Although the reader may expect from the introduction that farmaceutical paracetamol exposure will be discussed in relation to other exposures, mentioning of other exposures

e.g. exposure via secondary (non-pharmaceutical) sources, such as metabolic conversion from the ubiquitous industrial compound aniline are not well presented (although references are mentioned). Neither the possibility that paracetamol effects may depend on simultaneous exposures from environmental chemicals, e.g. phthalates, bisphenol A, and UV filters.

As discussed this review was intended to use paracetamol as one example of how the effects of exposure to endocrine disruptors are assessed. We have altered the manuscript (and the title) to reflect the fact that we do not discuss other 'EDCs' in detail. We have also mentioned the concept of 'mixtures' in relation to analgesic combinations (Page 7, Line 200-202). We agree that reference to other sources of paracetamol (e.g. aniline) is important and we have therefore included text (Page 10, Line 274-281) to highlight this.

- 4) Table 1 contains numerous important keywords of which only few are discussed. Furthermore it lacks a third group of studies where humans participate in endocrine studies with examinations of body fluids and cells (such studies are not just 'epidemiological'). Either the table legend should be expanded or the table deleted and replaced with a couple of sentences.

We agree that 'clinical studies' involving human participants are important approaches to the study of environmental and pharmaceutical exposures. However, they can still be broadly classified either as an 'experimental' or 'epidemiological' study depending on whether an intervention (experimental) was involved. Descriptive studies relating to exposures (including measured levels in bodily fluids) and associations with clinical outcomes etc can be classified as epidemiological studies. We have made some adjustments to the legend and discussed these factors throughout the text.

- 5) Table 2 is also difficult for an outsider to understand. It needs much more explanation (meaning of crosses?) and two symbols in a box is difficult to understand. The text should be expanded.

We agree that Table 2 will be difficult to understand so we have deleted the table. The points raised in the table are discussed throughout the text.

- 6) Fig 1. is somewhat misleading. If the authors believe that over/undernutrition can cause TDS they should include data. Anti-androgenic and estrogenic chemicals are mentioned. However, this whole field of endocrine disruptors has expanded during the past 10 years. The figure text could perhaps be used in a high school text book, but not in a scientific journal as Archives of Diseases in Childhood.

We agree that the list of 'potential' endocrine disruptors has increased dramatically over recent years and that this should be reflected in the text of the figure and we have modified this accordingly. The purpose of this introductory figure is simply to get across to a primarily general paediatric audience the idea that many exposures from a variety of different sources have been implicated as playing a role in the development of TDS disorders. We use ?? to highlight the fact that for many of these exposures their role in the development of TDS is still not clear.

- 7) Fig. 2 is somewhat confusing. The link between the gonocyte and germ cell cancer is not easy to spot. The group has previously produced TDS figures which were more helpful.

This figure is intended to describe testicular development across the lifecourse rather than to focus completely on mechanisms relating to TDS, hence the differences compared to our previously published figures on TDS origins and mechanisms. We refer to publications relating to TDS in which such figures are available. We agree with the reviewer that the relationship between gonocyte and GCNIS/TGCC is not illustrated in the current figure and we have modified the figure to explain this concept.

Reviewer: 2

Comments to the Author

This is a well written review and I have very few comments because of the quality of the writing and content

We thank the reviewer for the positive comments.

Page 3, line 14 – do the authors mean technical or practical difficulties? – presumably they simply mean that measuring this distance is embarrassing and not acceptable to humans? Is that correct?

The measurement of AGD is technically difficult in terms of accuracy of measurement and reproducibility as it depends on the expertise of the examiner and also requires accurate calibrated equipment. Practical difficulties relate to time required to measure and acceptability to patients in addition to clinical applicability for individual patients. We have modified this sentence to account for this (Page 3, Line 66-69).

Page 8, line 15 – presumably one form of exposure (in vitro) is continuous whereas in human plasma there are peaks and troughs?

This is correct and we have made reference to this in the text (Page 8, Line 238-242).

I think that using paracetamol as an illustration of the issues involved generally works. However the discussions are primarily about paracetamol and testosterone – which is (it can be argued) not of greatest interest because many of its' key effects occur following conversion to dihydrotestosterone or oestrogen. Could the authors discuss or comment?

It is true that DHT mediates some of the key masculinising effects in the male (e.g. external genitalia); however it is clear from rodent studies and clinical conditions that reductions in testosterone can result in TDS-like and masculinisation disorders which reflects the fact that testosterone is the primary precursor for DHT and oestrogen. Previous *in-vivo* rodent studies, investigating the effect of blocking both testosterone and DHT (via flutamide) in male fetuses results in subnormal AGD which correlates with incidence and severity of hypospadias, cryptorchidism, and reduced phallus length and seminal vesicle weight in males (Welsh et al 2008). We initially refer to androgens which would include DHT and testosterone, before focusing on testosterone which is known to be important for testicular descent.

I did wonder if readers would find a table listing the key agents that have been implicated in the evolution of disorders of reproduction / fertility of value .

We have increased the list in Figure 1 of EDCs that have been proposed to cause TDS disorders in response to this comment and that of Reviewer 1.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Page 11 line 10 – some are increasing...(remove ‘at least’)

This has been removed as requested.

Confidential: For Review Only

<u>Epidemiological</u>
Study Design - descriptive, case-control or experimental, relevant population
Exposure - measured directly (agent) or indirectly (questionnaire, proxy exposure)
Effect - direct effect (e.g. cryptorchidism) or indirect (AGD)
Other - mechanistic plausibility for effects

<u>Experimental</u>
Model - species, experimental system (e.g. <i>in-vivo</i> , <i>in-vitro</i> , <i>ex-vivo</i>)
Agent - same agent or similar class/compound, metabolism of agent
Dosing - dose equivalent (e.g. serum/ <i>in-vitro</i> concentrations), timing, duration
Effect - direct effect (e.g. cryptorchidism) or proxy for clinical condition (AGD)
Mechanism - e.g. effect on signalling pathways (including rescue)

Table 1 – Key points to consider when assessing epidemiological and experimental studies relating to the effects of environmental exposures on male reproductive development.

Lifestyle Factors

- Maternal smoking/ alcohol consumption
- Sedentary work/lifestyle
- Over/under nutrition
- Stress

Genetics

- Genetic Mutations
- Epigenetic Factors
- Fetal Growth

Environmental exposures

- Pharmaceuticals
e.g. analgesics
- Endocrine disrupting
chemicals/anti-androgenic
or estrogenic:
- Pesticides
- Phthalates
- Dioxins
- Perfluorinated compounds
- Ultraviolet filters

TDS Disorders

- Cryptorchidism
- Hypospadias
- Testicular Germ
Cell Cancer
- Low Sperm Count
- Primary Hypogonadism